Kimberly-Clark Corporation (KMB) Stock Forecast
Data as of Jun 16, 2026Consumer Defensive · Current price $103.82 (+0.70%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 14, 2026 | Lauren Lieberman | Barclays | $99.00 | -4.6% |
| Jan 28, 2026 | Peter Grom | UBS | $110.00 | +6.0% |
| Oct 28, 2025 | Nik Modi | RBC Capital | $162.00 | +56.0% |
| Oct 8, 2025 | Peter Grom | UBS | $130.00 | +25.2% |
| Oct 2, 2025 | Michael Lavery | Piper Sandler | $145.00 | +39.7% |
| Apr 23, 2025 | Korinne Wolfmeyer | Piper Sandler | $156.00 | +50.3% |
| Oct 22, 2024 | Ana Garcia | CFRA | $151.00 | +45.4% |
| Jul 24, 2024 | Steve Powers | Deutsche Bank | $142.00 | +36.8% |
| Jul 11, 2024 | Korrine Wolfmeyer | Piper Sandler | $174.00 | +67.6% |
| Jun 3, 2024 | Nik Modi | RBC Capital | $165.00 | +58.9% |
| Apr 25, 2024 | Lauren Lieberman | Barclays | $136.00 | +31.0% |
| Mar 28, 2024 | Steve Powers | Deutsche Bank | $132.00 | +27.1% |
| Mar 28, 2024 | Alejandro Zamacona | HSBC | $146.00 | +40.6% |
| Mar 28, 2024 | Javier Escalante | Evercore ISI | $150.00 | +44.5% |
| Mar 27, 2024 | Korinne Wolmeyer | Piper Sandler | $152.00 | +46.4% |
| Aug 7, 2023 | Dara Mohsenian | Morgan Stanley | $153.00 | +47.4% |
| Apr 6, 2023 | Stephanie Wissink | Jefferies | $150.00 | +44.5% |
| Apr 28, 2022 | Lauren Lieberman | Barclays | $129.00 | +24.3% |
| Apr 25, 2022 | Steve Powers | Deutsche Bank | $138.00 | +32.9% |
| Apr 25, 2022 | Nik Modi | RBC Capital | $124.00 | +19.4% |
Top Analysts Covering KMB
KMB vs Sector & Market
| Metric | KMB | Consumer Defensive Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.00 | 2.55 | 2.40 |
| Analyst Count | 12 | 11 | 19 |
| Target Upside | -1.0% | +923.8% | +17.1% |
| P/E Ratio | 16.30 | 11.40 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $17.30B | $17.42B | $17.61B | 10 |
| 2027-03-31 | $4.09B | $4.16B | $4.23B | 3 |
| 2027-06-30 | $4.29B | $4.36B | $4.44B | 3 |
| 2027-09-30 | $4.29B | $4.37B | $4.44B | 3 |
| 2027-12-31 | $4.23B | $4.30B | $4.37B | 3 |
| 2028-03-31 | $6.25B | $6.35B | $6.46B | 2 |
| 2028-06-30 | $6.40B | $6.50B | $6.61B | 2 |
| 2028-09-30 | $6.37B | $6.48B | $6.59B | 2 |
| 2028-12-31 | $6.32B | $6.43B | $6.54B | 2 |
| 2029-12-31 | $23.36B | $23.69B | $25.44B | 5 |
| 2030-12-31 | $26.75B | $27.13B | $29.14B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $7.42 | $7.49 | $7.55 | 8 |
| 2027-03-31 | $1.68 | $1.72 | $1.76 | 3 |
| 2027-06-30 | $1.88 | $1.92 | $1.97 | 2 |
| 2027-09-30 | $1.89 | $1.93 | $1.97 | 2 |
| 2027-12-31 | $1.77 | $1.81 | $1.85 | 2 |
| 2028-03-31 | $1.81 | $1.85 | $1.89 | 3 |
| 2028-06-30 | $2.05 | $2.09 | $2.14 | 6 |
| 2028-09-30 | $2.06 | $2.10 | $2.15 | 5 |
| 2028-12-31 | $1.94 | $1.98 | $2.02 | 5 |
| 2029-12-31 | $8.39 | $8.54 | $9.37 | 1 |
| 2030-12-31 | $8.90 | $9.06 | $9.93 | 1 |
Frequently Asked Questions
What is the analyst consensus for KMB?
The consensus among 12 analysts covering Kimberly-Clark Corporation (KMB) is Hold with an average price target of $119.86.
What is the highest price target for KMB?
The highest price target for KMB is $174.00, set by Korrine Wolfmeyer at Piper Sandler on 2024-07-11.
What is the lowest price target for KMB?
The lowest price target for KMB is $99.00, set by Lauren Lieberman at Barclays on 2026-04-14.
How many analysts cover KMB?
12 analysts have issued ratings for Kimberly-Clark Corporation in the past 12 months.
Is KMB a buy or sell right now?
Based on 12 analyst ratings, KMB has a consensus rating of Hold (3.00/5) with a -1.0% upside to the consensus target of $119.86.
What are the earnings estimates for KMB?
Analysts estimate KMB will report EPS of $7.49 for the period ending 2026-12-31, with revenue estimated at $17.42B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.